Strattera (Atomoxetine) Supply Issues: What Providers and Prescribers Need to Know in 2026

Patients taking atomoxetine have encountered a series of supply-side disruptions over the past few years: the discontinuation of brand-name Strattera by Eli Lilly in November 2023, followed by Glenmark's recall of approximately 1.48 million bottles of generic atomoxetine in January 2025. For prescribers managing ADHD patients on this medication, understanding the current landscape — and having clear protocols for when patients can't fill their prescriptions — is essential to maintaining continuity of care.

Clinical Context: Where Atomoxetine Fits in ADHD Treatment

Atomoxetine is FDA-approved for ADHD in children ages 6 and older, adolescents, and adults. As the first non-stimulant ADHD medication approved by the FDA (2002), it holds an important niche in the treatment algorithm — particularly for patients where stimulants are contraindicated or suboptimal:

Patients with comorbid anxiety disorders (stimulants can exacerbate anxiety)

Patients with personal or family history of substance use disorder (no abuse potential with atomoxetine)

Patients experiencing intolerable stimulant side effects (insomnia, appetite suppression, rebound)

Patients who prefer a non-controlled substance due to work, military, or professional licensing concerns

Patients with poor stimulant response who need a different mechanism of action

The American Academy of Child and Adolescent Psychiatry (AACAP) classifies atomoxetine as a second- or third-line option for ADHD due to its smaller average effect size compared to stimulants. However, for the patient populations listed above, it is often the preferred first-line choice.

The Supply Timeline: What Happened and When

November 2023: Brand-Name Strattera Discontinuation

Eli Lilly discontinued all strengths of brand-name Strattera in November 2023. This was a commercial decision following significant market share erosion to generics after patent expiration in 2017. From a clinical standpoint, this transition required prescribers to update prescriptions from "Strattera" to "atomoxetine" (or ensure "dispense as written" was not selected), and required patient education about the transition to generic.

January 2025: Glenmark Class II Voluntary Recall

Glenmark Pharmaceuticals issued a voluntary recall of approximately 1.48 million bottles of generic atomoxetine across all strengths (10 mg–100 mg) beginning January 29, 2025. The reason: unacceptable levels of N-nitroso atomoxetine (NATX), a probable human carcinogen (IARC Class 2A), detected in multiple lots manufactured at Glenmark's Goa, India facility.

The FDA classified this as a Class II recall — meaning use of the recalled products may cause temporary or reversible adverse consequences, but the probability of serious adverse health consequences is remote. Patients who had been using Glenmark's atomoxetine were advised to consult their healthcare providers. The recall did not affect products from other manufacturers (Teva, Aurobindo, Zydus, Hikma, etc.).

Current Supply Status (2026)

As of 2026, generic atomoxetine is not on the FDA's active drug shortage list. The market has at least nine active generic manufacturers. However, individual pharmacy stock can still vary by dose and location — particularly for less-common doses (10 mg, 18 mg) or in areas where Glenmark was the dominant supplier prior to the recall.

Clinical Guidance: When a Patient Can't Fill Their Atomoxetine

When patients report difficulty filling their atomoxetine prescription, the following stepwise approach is recommended:

Confirm availability before switching: Many apparent shortages are localized to one pharmacy. Encourage patients to check multiple pharmacies or use a service like medfinder before assuming the medication is unavailable.

Consider mail-order: Atomoxetine is not a controlled substance, so there are no restrictions on mail-order dispensing. 90-day supplies via mail order are appropriate.

Bridge with existing supply: Patients may be able to bridge with partial fills. Unlike stimulants, atomoxetine patients don't need to stop treatment immediately when they miss a dose — but consistent daily dosing is important for therapeutic effect.

If substitution is necessary: Viloxazine ER (Qelbree) is the most pharmacologically similar alternative. For pediatric patients (6–17), guanfacine ER (Intuniv) or clonidine ER (Kapvay) are alternatives. Adult patients may be candidates for bupropion (off-label) or stimulant therapy if clinically appropriate.

Transitioning Patients From Atomoxetine to an Alternative

Key clinical considerations when transitioning:

Atomoxetine does not require gradual tapering to discontinue (unlike guanfacine and clonidine, which require dose tapering to avoid rebound hypertension).

Qelbree and atomoxetine should not be used concurrently (same mechanism; additive risk without additional benefit).

When adding guanfacine or clonidine as a bridge while searching for atomoxetine, monitor blood pressure carefully.

Switching to stimulants requires assessing for contraindications (cardiac history, active substance use disorder, personal/family history of psychosis or bipolar disorder).

How to Help Your Patients Find Atomoxetine

Providers can recommend medfinder for providers as a tool for patients struggling to locate their medication. medfinder contacts pharmacies on the patient's behalf, checking which ones have the specific medication and dose in stock, then texts results to the patient. This eliminates the time burden on patients and staff.

Documentation and Prescribing Notes

For prescriptions, use "atomoxetine" (not "Strattera") as the drug name to avoid confusion at the pharmacy level. If a patient has a CYP2D6 phenotype issue or has been on fluoxetine, paroxetine, or quinidine, note the pharmacogenetic interaction in the chart — poor CYP2D6 metabolizers should be capped at 40 mg/day, and patients on CYP2D6 inhibitors require dose adjustment or closer monitoring.

The Bottom Line for Providers

Generic atomoxetine is not in national shortage as of 2026, but localized disruptions remain real. A proactive approach — anticipating patient difficulty finding medication and having a clear substitution protocol — minimizes treatment gaps. See our companion guide: How to Help Your Patients Find Strattera in Stock.